Microbot Medical has crossed from a decade of development into a commercial company, and the second-quarter print is the first clean look at whether hospitals actually buy the LIBERTY Endovascular Robotic System once the limited launch ends. The Food and Drug Administration granted marketing clearance in September 2025. A limited market release followed in November, and the full market release opened at the Society of Interventional Radiology meeting in April. Sequential revenue more than doubled as new health systems in Massachusetts, North Carolina, Michigan, and Pennsylvania joined earlier adopters in Georgia, Florida, and New York. The debate is no longer whether a disposable, remotely operated peripheral robot can be cleared. The debate is whether early hospital orders compound into a business that can cover its own manufacturing and selling cost.
That is a harder test than clearance. First-half product sales reached only $346 thousand against a cash operating outflow of $10 million. Second-quarter sales of $241 thousand more than doubled the opening commercial quarter, yet cost of revenue still produced a gross loss. Inventory has been built ahead of demand, and selling expense has been staffed for a national footprint that is only eight territories wide. The balance sheet is the reason the story is still alive. Cash and marketable securities of $67 million sit against almost no funded debt, and management states that runway covers more than twelve months. The market is capitalizing the equity at roughly $91 million, which ascribes a modest franchise premium above cash rather than a scaled device company.
The next several quarters resolve a simple question. Does utilization inside existing health systems, plus new sites and a second manufacturing node at Sanmina, pull cost of revenue down as the sales map expands toward a planned twelve territories? Or does LIBERTY remain a high-touch, negative-margin placement whose cash burn forces another equity raise while a large at-the-market shelf and a warrant overhang sit unused above the tape? The strongest counterargument is that sequential doubling off a tiny base is what every early device launch looks like, and that a twenty-patient pivotal study is not the same thing as hospital-wide standard of care.